Schizophrenia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Schizophrenia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Schizophrenia - Drugs In Development, 2022, provides an overview of the Schizophrenia (Central Nervous System) pipeline landscape.

Schizophrenia is a chronic, severe, and disabling brain disorder that generally appears in late adolescence or early adulthood. Symptoms include delusions, hallucinations, disorganized speech and disorganized behavior. Risk factors include family history, age, drugs (psychoactive) and weakened immune system. Treatment includes antipsychotic medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Schizophrenia - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Schizophrenia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Schizophrenia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Schizophrenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 4, 15, 14, 24, 5, 62, 23 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 1, 5 and 1 molecules, respectively.

Schizophrenia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Schizophrenia (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Schizophrenia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Schizophrenia (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Schizophrenia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Schizophrenia (Central Nervous System)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Schizophrenia (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Schizophrenia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Schizophrenia – Overview
Schizophrenia – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Schizophrenia – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Schizophrenia – Companies Involved in Therapeutics Development
3Z ehf
AbbVie Inc
Acadia Pharmaceuticals Inc
Adamed Pharma SA
Adare Pharma Solutions
Addex Therapeutics Ltd
AgeneBio Inc
AgoneX Biopharmaceuticals Inc
Alexza Pharmaceuticals Inc
Ananda Scientific Inc
Anavex Life Sciences Corp
Athira Pharma Inc
Autifony Therapeutics Ltd
Avanir Pharmaceuticals Inc
Avicanna Inc
BCWorld Pharm Co Ltd
Benuvia Therapeutics Inc
Biogen Inc
BioXcel Therapeutics Inc
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Celon Pharma SA
Cerevance Inc
Cerevel Therapeutics Holdings Inc
Curemark LLC
CuroNZ Ltd
Cyclerion Therapeutics Inc
Daewoong Pharmaceutical Co Ltd
Daya Drug Discoveries Inc
Delpor Inc
Denovo Biopharma LLC
Echo Pharmaceuticals BV
Endosane Pharmaceuticals GmbH
Entheogenix Biosciences Inc
Exscientia Plc
F. Hoffmann-La Roche Ltd
Gabather AB
Gedeon Richter Plc
Genochem SAS
GP Pharm SA
H. Lundbeck AS
Intra-Cellular Therapies Inc
Io Therapeutics Inc
Jaguar Health Inc
Jazz Pharmaceuticals Plc
Jiangsu Enhua Pharmaceutical Group Co Ltd
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Jiangsu Nhwa Pharmaceutical Co Ltd
Johnson & Johnson
Karuna Therapeutics Inc
Laboratorios Farmaceuticos Rovi SA
LB Pharmaceuticals Inc
Lead Discovery Center GmbH
Livzon Pharmaceutical Group Co Ltd
Lohocla Research Corp
Luye Pharma Group Ltd
Lyndra Therapeutics Inc.
Malachite Innovations Inc
MapLight therapeutics Inc
MedinCell SA
Mental-Heal Ltd
Merck & Co Inc
Midatech Pharma Plc
Mitsubishi Tanabe Pharma Corp
Nanomi BV
Neonc Technologies Inc
Neumora Therapeutics Inc
Neurelis Inc
Neurocrine Biosciences Inc
NeurOp Inc
NeuroSolis Inc
Newron Pharmaceuticals SpA
Nostrum Biodiscovery SL
Novartis AG
Omeros Corp
Oryzon Genomics SA
Otsuka Pharmaceutical Co Ltd
OWP Pharmaceuticals Inc
Pasithea Therapeutics Corp
ProMIS Neurosciences Inc
Ra Pharmaceuticals Inc
Reviva Pharmaceuticals Inc
Saniona AB
Shanghai Pharmaceutical Group Co Ltd
Shanghai Zhongze Medicine Tech Co Ltd
Sichuan Kelun Pharmaceutical Co Ltd
Siragen Pharmaceuticals Inc
Sirtsei Pharmaceuticals Inc
SkySea Pharmaceutical Inc
Sosei Group Corp
Sumitomo Pharma Co Ltd
Sunovion Pharmaceuticals Inc
Suven Life Sciences Ltd
SyneuRx International (Taiwan) Corp
Taho Pharmaceuticals Ltd
Taisho Pharmaceutical Holdings Co Ltd
Takeda Pharmaceutical Co Ltd
Terran Biosciences Inc
Teva Pharmaceutical Industries Ltd
The Greater Cannabis Company Inc
Therapeutic Solutions International Inc
Valentec
Vanda Pharmaceuticals Inc
Verge Genomics
Vivozon Inc
Whan In Pharm Co Ltd
YaoPharma Co Ltd
Yoda Pharmaceuticals Inc
Zhejiang Jingxin Pharmaceutical Co Ltd
Schizophrenia – Drug Profiles
(deudextromethorphan hydrobromide + quinidine sulfate) – Drug Profile
(trospium chloride + xanomeline) – Drug Profile
ADN-2013 – Drug Profile
AGB-473 – Drug Profile
Alstonine – Drug Profile
ANAVEX-371 – Drug Profile
aripiprazole – Drug Profile
aripiprazole ER – Drug Profile
asenapine – Drug Profile
ATH-1020 – Drug Profile
AUT-00201 – Drug Profile
AUT-00206 – Drug Profile
AZ-104 – Drug Profile
Back Up Modulators – Drug Profile
BCWPD-010 – Drug Profile
BMS-910731 – Drug Profile
BMS-952048 – Drug Profile
BMT-133218 – Drug Profile
brexpiprazole – Drug Profile
brexpiprazole SR – Drug Profile
brilaroxazine – Drug Profile
CampbellCell – Drug Profile
cannabidiol – Drug Profile
cariprazine – Drug Profile
clozapine – Drug Profile
CM-182 – Drug Profile
CPL-500036 – Drug Profile
CVL-047 – Drug Profile
CVN-058 – Drug Profile
CY-150112 – Drug Profile
CY-6463 – Drug Profile
DDD-016 – Drug Profile
dexmedetomidine – Drug Profile
DISC1 – Drug Profile
Drug for Schizophrenia – Drug Profile
Dual Muscarinic M1/M4 agonists – Drug Profile
ECP-012A – Drug Profile
emraclidine – Drug Profile
evenamide – Drug Profile
Gene Therapy to Activate DAT for Addictive Disorders and Schizophrenia – Drug Profile
GPR52 agonist – Drug Profile
GT-002 – Drug Profile
histamine dihydrochloride – Drug Profile
HS-10380 – Drug Profile
iloperidone – Drug Profile
iloperidone LAI – Drug Profile
IRX-4204 – Drug Profile
JNJ-1813 – Drug Profile
JX-11502MA – Drug Profile
LB-102 – Drug Profile
LB-102 LA – Drug Profile
LOT-001 – Drug Profile
LuAE-98134 – Drug Profile
lumateperone tosylate – Drug Profile
lurasidone hydrochloride – Drug Profile
M4 agonist program – Drug Profile
M4 PAM – Drug Profile
MDC-ANG – Drug Profile
MDC-TJK – Drug Profile
MK-8189 – Drug Profile
ML-007 – Drug Profile
NBD-04 – Drug Profile
NBI-1117568 – Drug Profile
NEO-216 – Drug Profile
New Compounds – Drug Profile
NH-300094 – Drug Profile
NMRA-M4R – Drug Profile
NRL-4 – Drug Profile
NSX-0527 – Drug Profile
NSX-0527f – Drug Profile
NSX-0559 – Drug Profile
NSX-0559f – Drug Profile
OAK-0011799 – Drug Profile
paliperidone palmitate – Drug Profile
PAT-101 – Drug Profile
PF-06412562 – Drug Profile
PG-14 – Drug Profile
PGW-5 – Drug Profile
pimavanserin tartrate – Drug Profile
pomaglumetad methionil – Drug Profile
PyP-1 – Drug Profile
quetiapine fumarate – Drug Profile
ralmitaront – Drug Profile
risperidone – Drug Profile
risperidone ER – Drug Profile
risperidone LA – Drug Profile
risperidone PR – Drug Profile
risperidone SR – Drug Profile
rituximab – Drug Profile
roluperidone – Drug Profile
RSD-7 – Drug Profile
Small Molecule for Neurolological Disorders – Drug Profile
Small Molecule for Schizophrenia – Drug Profile
Small Molecule for Schizophrenia and Cardiovascular Diseases – Drug Profile
Small Molecule to Agonize GPR52 for Schizophrenia – Drug Profile
Small Molecule to Agonize Muscarinic Acetylcholine Receptor M1 for Schizophrenia – Drug Profile
Small Molecule to Agonize Muscarinic Acetylcholine Receptor M4 for Schizophrenia – Drug Profile
Small Molecule to Antagonize 5-HT2A Receptor for Schizophrenia – Drug Profile
Small Molecule to Antagonize DRD2 for CNS Disorders and Hormonal Disorders – Drug Profile
Small Molecule to Antagonize GPR173 for Obesity and Schizophrenia – Drug Profile
Small Molecule to Antagonize GPR27 for Diabetes, Obesity and Schizophrenia – Drug Profile
Small Molecule to Antagonize GPR78 for Bipolar Disorder and Schizophrenia – Drug Profile
Small Molecule to Antagonize GPR85 for Obesity and Schizophrenia – Drug Profile
Small Molecule to Inhibit GlyT1 for Parkinson’s Disease and Schizophrenia – Drug Profile
Small Molecule to Inhibit Serotonin, Histamine and Dopamine Receptors for Schizophrenia – Drug Profile
Small Molecule to Target GPR151 for CNS Diseases and Metabolic Disorders – Drug Profile
Small Molecule to Target GPR153 for Schizophrenia – Drug Profile
Small Molecules 2 to Agonize Muscarinic Acetylcholine Receptor M1 for Alzheimer's Disease and Schizophrenia – Drug Profile
Small Molecules for Depression and Schizophrenia – Drug Profile
Small Molecules for Frontotemporal Dementia, Lewy Body Dementia, Progressive Supranuclear Palsy and Schizophrenia – Drug Profile
Small Molecules for Psychiatric Disorders – Drug Profile
Small Molecules for Schizophrenia – Drug Profile
Small Molecules to Agonize CB1 and CB2 for Central Nervous System Disorders – Drug Profile
Small Molecules to Agonize CHRNA7 for Central Nervous System – Drug Profile
Small Molecules to Agonize GABRA5 for Schizophrenia and Autism – Drug Profile
Small Molecules to Agonize mGlu1 for Schizophrenia – Drug Profile
Small Molecules to Agonize mGluR5 for Schizophrenia – Drug Profile
Small Molecules to Agonize Muscarinic Acetylcholine Receptor M1 for Alzheimer's Disease and Schizophrenia – Drug Profile
Small Molecules to Agonize NMDA Receptor for Schizophrenia – Drug Profile
Small Molecules to Agonize NMDAR for Schizophrenia – Drug Profile
Small Molecules to Inhibit Glyt1 for Schizophrenia – Drug Profile
Small Molecules to Inhibit PDE10A for Schizophrenia – Drug Profile
Small Molecules to Inhibit PDE2 for CNS Disorders – Drug Profile
Small Molecules to Target GPCR for Schizophrenia – Drug Profile
sodium benzoate – Drug Profile
SP-624 – Drug Profile
SUVNI-6107 – Drug Profile
Synthetic Peptide for Neurological and Psychiatric Diseases – Drug Profile
Synthetic Peptide for Schizophrenia – Drug Profile
Synthetic Peptide to Antagonize VIPR2 for Schizophrenia – Drug Profile
Synthetic Peptides to Inhibit Complement C1s for Autoimmune Disorders, Neurodegenerative Diseases, Kidney Diseases and Schizophrenia – Drug Profile
TAH-7702 – Drug Profile
tetrahydropalamatine – Drug Profile
TEV-44749 – Drug Profile
TEV-48438 – Drug Profile
THPP-1 – Drug Profile
TPN-672 – Drug Profile
TR-01 – Drug Profile
TR-36 – Drug Profile
TS-134 – Drug Profile
ulotaront – Drug Profile
vafidemstat – Drug Profile
valbenazine tosylate – Drug Profile
VHX-896 – Drug Profile
VLT-015 – Drug Profile
VVZN-3 – Drug Profile
YA-101 – Drug Profile
ZZ-6398 – Drug Profile
Schizophrenia – Dormant Projects
Schizophrenia – Discontinued Products
Schizophrenia – Product Development Milestones
Featured News & Press Releases
Sep 21, 2022: CADTH recommendation to not reimburse new treatment a failure for people living with schizophrenia
Sep 13, 2022: Otsuka and Lundbeck Announce U.S. FDA Acceptance of New Drug Application for Aripiprazole 2-month, Ready-to-Use, Long-acting Injectable to Treat Schizophrenia and Bipolar I Disorder in Adults
Aug 29, 2022: Phase 3 study to be initiated for second long-acting injectable antipsychotic using MedinCell’s technology
Aug 23, 2022: Segal Trials participation in study shows positive results from phase 3 EMERGENT-2 KarXT in schizophrenia
Aug 22, 2022: Minerva Neurosciences submits new drug application to FDA for roluperidone for the treatment of negative symptoms in patients with schizophrenia
Aug 19, 2022: Maplight concludes Phase I trial of schizophrenia and dyskinesia therapy
Aug 08, 2022: Karuna reports positive Phase III KarXT data in schizophrenia
Aug 04, 2022: Sosei Heptares’ oral, selective M4 receptor agonist advancing into phase 2 clinical development under multi-program collaboration with Neurocrine Biosciences
Jul 27, 2022: Reviva Pharmaceuticals provides update on clinical development pipeline
Jul 19, 2022: LB announces publication of phase 1 clinical study of LB-102
Jul 14, 2022: Shanghai Fosun Pharmaceuticals: Announcement in relation to acceptance of a subsidiary’s drug registration application
Jun 16, 2022: European Medicines Agency commences review of Aripiprazole2-month long-acting injectable for the maintenance treatment of Schizophrenia in adult patients stabilised with Aripiprazole
Jun 07, 2022: Newron presents encouraging interim results for evenamide in patients with Treatment-Resistant Schizophrenia (TRS) at the 33rd CINP Hybrid World Congress of Neuropsychopharmacology
May 03, 2022: Reviva Pharmaceuticals to host key opinion leader webinar on brilaroxazine for schizophrenia and Other neuropsychiatric disorders
May 03, 2022: Reviva Pharmaceuticals announces update on RECOVER, a pivotal phase 3 global study evaluating brilaroxazine for the treatment of schizophrenia
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Table 1: Number of Products under Development for Schizophrenia, 2022
Table 2: Number of Products under Development by Companies, 2022
Table 3: Number of Products under Development by Companies, 2022 (Contd..1)
Table 4: Number of Products under Development by Companies, 2022 (Contd..2)
Table 5: Number of Products under Development by Companies, 2022 (Contd..3)
Table 6: Number of Products under Development by Companies, 2022 (Contd..4)
Table 7: Number of Products under Development by Companies, 2022 (Contd..5)
Table 8: Number of Products under Development by Universities/Institutes, 2022
Table 9: Products under Development by Companies, 2022
Table 10: Products under Development by Companies, 2022 (Contd..1)
Table 11: Products under Development by Companies, 2022 (Contd..2)
Table 12: Products under Development by Companies, 2022 (Contd..3)
Table 13: Products under Development by Companies, 2022 (Contd..4)
Table 14: Products under Development by Companies, 2022 (Contd..5)
Table 15: Products under Development by Companies, 2022 (Contd..6)
Table 16: Products under Development by Companies, 2022 (Contd..7)
Table 17: Products under Development by Companies, 2022 (Contd..8)
Table 18: Products under Development by Universities/Institutes, 2022
Table 19: Number of Products by Stage and Target, 2022
Table 20: Number of Products by Stage and Target, 2022 (Contd..1)
Table 21: Number of Products by Stage and Target, 2022 (Contd..2)
Table 22: Number of Products by Stage and Target, 2022 (Contd..3)
Table 23: Number of Products by Stage and Mechanism of Action, 2022
Table 24: Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
Table 25: Number of Products by Stage and Mechanism of Action, 2022 (Contd..2)
Table 26: Number of Products by Stage and Mechanism of Action, 2022 (Contd..3)
Table 27: Number of Products by Stage and Route of Administration, 2022
Table 28: Number of Products by Stage and Molecule Type, 2022
Table 29: Schizophrenia – Pipeline by 3Z ehf, 2022
Table 30: Schizophrenia – Pipeline by AbbVie Inc, 2022
Table 31: Schizophrenia – Pipeline by Acadia Pharmaceuticals Inc, 2022
Table 32: Schizophrenia – Pipeline by Adamed Pharma SA, 2022
Table 33: Schizophrenia – Pipeline by Adare Pharma Solutions, 2022
Table 34: Schizophrenia – Pipeline by Addex Therapeutics Ltd, 2022
Table 35: Schizophrenia – Pipeline by AgeneBio Inc, 2022
Table 36: Schizophrenia – Pipeline by AgoneX Biopharmaceuticals Inc, 2022
Table 37: Schizophrenia – Pipeline by Alexza Pharmaceuticals Inc, 2022
Table 38: Schizophrenia – Pipeline by Ananda Scientific Inc, 2022
Table 39: Schizophrenia – Pipeline by Anavex Life Sciences Corp, 2022
Table 40: Schizophrenia – Pipeline by Athira Pharma Inc, 2022
Table 41: Schizophrenia – Pipeline by Autifony Therapeutics Ltd, 2022
Table 42: Schizophrenia – Pipeline by Avanir Pharmaceuticals Inc, 2022
Table 43: Schizophrenia – Pipeline by Avicanna Inc, 2022
Table 44: Schizophrenia – Pipeline by BCWorld Pharm Co Ltd, 2022
Table 45: Schizophrenia – Pipeline by Benuvia Therapeutics Inc, 2022
Table 46: Schizophrenia – Pipeline by Biogen Inc, 2022
Table 47: Schizophrenia – Pipeline by BioXcel Therapeutics Inc, 2022
Table 48: Schizophrenia – Pipeline by Boehringer Ingelheim International GmbH, 2022
Table 49: Schizophrenia – Pipeline by Bristol-Myers Squibb Co, 2022
Table 50: Schizophrenia – Pipeline by Celon Pharma SA, 2022
Table 51: Schizophrenia – Pipeline by Cerevance Inc, 2022
Table 52: Schizophrenia – Pipeline by Cerevel Therapeutics Holdings Inc, 2022
Table 53: Schizophrenia – Pipeline by Curemark LLC, 2022
Table 54: Schizophrenia – Pipeline by CuroNZ Ltd, 2022
Table 55: Schizophrenia – Pipeline by Cyclerion Therapeutics Inc, 2022
Table 56: Schizophrenia – Pipeline by Daewoong Pharmaceutical Co Ltd, 2022
Table 57: Schizophrenia – Pipeline by Daya Drug Discoveries Inc, 2022
Table 58: Schizophrenia – Pipeline by Delpor Inc, 2022
Table 59: Schizophrenia – Pipeline by Denovo Biopharma LLC, 2022
Table 60: Schizophrenia – Pipeline by Echo Pharmaceuticals BV, 2022
Table 61: Schizophrenia – Pipeline by Endosane Pharmaceuticals GmbH, 2022
Table 62: Schizophrenia – Pipeline by Entheogenix Biosciences Inc, 2022
Table 63: Schizophrenia – Pipeline by Exscientia Plc, 2022
Table 64: Schizophrenia – Pipeline by F. Hoffmann-La Roche Ltd, 2022
Table 65: Schizophrenia – Pipeline by Gabather AB, 2022
Table 66: Schizophrenia – Pipeline by Gedeon Richter Plc, 2022
Table 67: Schizophrenia – Pipeline by Genochem SAS, 2022
Table 68: Schizophrenia – Pipeline by GP Pharm SA, 2022
Table 69: Schizophrenia – Pipeline by H. Lundbeck AS, 2022
Table 70: Schizophrenia – Pipeline by Intra-Cellular Therapies Inc, 2022
Table 71: Schizophrenia – Pipeline by Io Therapeutics Inc, 2022
Table 72: Schizophrenia – Pipeline by Jaguar Health Inc, 2022
Table 73: Schizophrenia – Pipeline by Jazz Pharmaceuticals Plc, 2022
Table 74: Schizophrenia – Pipeline by Jiangsu Enhua Pharmaceutical Group Co Ltd, 2022
Table 75: Schizophrenia – Pipeline by Jiangsu Hansoh Pharmaceutical Group Co Ltd, 2022
Table 76: Schizophrenia – Pipeline by Jiangsu Nhwa Pharmaceutical Co Ltd, 2022
Table 77: Schizophrenia – Pipeline by Johnson & Johnson, 2022
Table 78: Schizophrenia – Pipeline by Karuna Therapeutics Inc, 2022
Table 79: Schizophrenia – Pipeline by Laboratorios Farmaceuticos Rovi SA, 2022
Table 80: Schizophrenia – Pipeline by LB Pharmaceuticals Inc, 2022
Table 81: Schizophrenia – Pipeline by Lead Discovery Center GmbH, 2022
Table 82: Schizophrenia – Pipeline by Livzon Pharmaceutical Group Co Ltd, 2022
Table 83: Schizophrenia – Pipeline by Lohocla Research Corp, 2022
Table 84: Schizophrenia – Pipeline by Luye Pharma Group Ltd, 2022
Table 85: Schizophrenia – Pipeline by Lyndra Therapeutics Inc., 2022
Table 86: Schizophrenia – Pipeline by Malachite Innovations Inc, 2022
Table 87: Schizophrenia – Pipeline by MapLight therapeutics Inc, 2022
Table 88: Schizophrenia – Pipeline by MedinCell SA, 2022
Table 89: Schizophrenia – Pipeline by Mental-Heal Ltd, 2022
Table 90: Schizophrenia – Pipeline by Merck & Co Inc, 2022
Table 91: Schizophrenia – Pipeline by Midatech Pharma Plc, 2022
Table 92: Schizophrenia – Pipeline by Mitsubishi Tanabe Pharma Corp, 2022
Table 93: Schizophrenia – Pipeline by Nanomi BV, 2022
Table 94: Schizophrenia – Pipeline by Neonc Technologies Inc, 2022
Table 95: Schizophrenia – Pipeline by Neumora Therapeutics Inc, 2022
Table 96: Schizophrenia – Pipeline by Neurelis Inc, 2022
Table 97: Schizophrenia – Pipeline by Neurocrine Biosciences Inc, 2022
Table 98: Schizophrenia – Pipeline by NeurOp Inc, 2022
Table 99: Schizophrenia – Pipeline by NeuroSolis Inc, 2022
Table 100: Schizophrenia – Pipeline by Newron Pharmaceuticals SpA, 2022
Table 101: Schizophrenia – Pipeline by Nostrum Biodiscovery SL, 2022
Table 102: Schizophrenia – Pipeline by Novartis AG, 2022
Table 103: Schizophrenia – Pipeline by Omeros Corp, 2022
Table 104: Schizophrenia – Pipeline by Oryzon Genomics SA, 2022
Table 105: Schizophrenia – Pipeline by Otsuka Pharmaceutical Co Ltd, 2022
Table 106: Schizophrenia – Pipeline by OWP Pharmaceuticals Inc, 2022
Table 107: Schizophrenia – Pipeline by Pasithea Therapeutics Corp, 2022
Table 108: Schizophrenia – Pipeline by ProMIS Neurosciences Inc, 2022
Table 109: Schizophrenia – Pipeline by Ra Pharmaceuticals Inc, 2022
Table 110: Schizophrenia – Pipeline by Reviva Pharmaceuticals Inc, 2022
Table 111: Schizophrenia – Pipeline by Saniona AB, 2022
Table 112: Schizophrenia – Pipeline by Shanghai Pharmaceutical Group Co Ltd, 2022
Table 113: Schizophrenia – Pipeline by Shanghai Zhongze Medicine Tech Co Ltd, 2022
Table 114: Schizophrenia – Pipeline by Sichuan Kelun Pharmaceutical Co Ltd, 2022
Table 115: Schizophrenia – Pipeline by Siragen Pharmaceuticals Inc, 2022
Table 116: Schizophrenia – Pipeline by Sirtsei Pharmaceuticals Inc, 2022
Table 117: Schizophrenia – Pipeline by SkySea Pharmaceutical Inc, 2022
Table 118: Schizophrenia – Pipeline by Sosei Group Corp, 2022
Table 119: Schizophrenia – Pipeline by Sumitomo Pharma Co Ltd, 2022
Table 120: Schizophrenia – Pipeline by Sunovion Pharmaceuticals Inc, 2022
Table 121: Schizophrenia – Pipeline by Suven Life Sciences Ltd, 2022
Table 122: Schizophrenia – Pipeline by SyneuRx International (Taiwan) Corp, 2022
Table 123: Schizophrenia – Pipeline by Taho Pharmaceuticals Ltd, 2022
Table 124: Schizophrenia – Pipeline by Taisho Pharmaceutical Holdings Co Ltd, 2022
Table 125: Schizophrenia – Pipeline by Takeda Pharmaceutical Co Ltd, 2022
Table 126: Schizophrenia – Pipeline by Terran Biosciences Inc, 2022
Table 127: Schizophrenia – Pipeline by Teva Pharmaceutical Industries Ltd, 2022
Table 128: Schizophrenia – Pipeline by The Greater Cannabis Company Inc, 2022
Table 129: Schizophrenia – Pipeline by Therapeutic Solutions International Inc, 2022
Table 130: Schizophrenia – Pipeline by Valentec, 2022
Table 131: Schizophrenia – Pipeline by Vanda Pharmaceuticals Inc, 2022
Table 132: Schizophrenia – Pipeline by Verge Genomics, 2022
Table 133: Schizophrenia – Pipeline by Vivozon Inc, 2022
Table 134: Schizophrenia – Pipeline by Whan In Pharm Co Ltd, 2022
Table 135: Schizophrenia – Pipeline by YaoPharma Co Ltd, 2022
Table 136: Schizophrenia – Pipeline by Yoda Pharmaceuticals Inc, 2022
Table 137: Schizophrenia – Pipeline by Zhejiang Jingxin Pharmaceutical Co Ltd, 2022
Table 138: Schizophrenia – Dormant Projects, 2022
Table 139: Schizophrenia – Dormant Projects, 2022 (Contd..1)
Table 140: Schizophrenia – Dormant Projects, 2022 (Contd..2)
Table 141: Schizophrenia – Dormant Projects, 2022 (Contd..3)
Table 142: Schizophrenia – Dormant Projects, 2022 (Contd..4)
Table 143: Schizophrenia – Dormant Projects, 2022 (Contd..5)
Table 144: Schizophrenia – Dormant Projects, 2022 (Contd..6)
Table 145: Schizophrenia – Dormant Projects, 2022 (Contd..7)
Table 146: Schizophrenia – Dormant Projects, 2022 (Contd..8)
Table 147: Schizophrenia – Dormant Projects, 2022 (Contd..9)
Table 148: Schizophrenia – Dormant Projects, 2022 (Contd..10)
Table 149: Schizophrenia – Dormant Projects, 2022 (Contd..11)
Table 150: Schizophrenia – Discontinued Products, 2022
Table 151: Schizophrenia – Discontinued Products, 2022 (Contd..1)
Table 152: Schizophrenia – Discontinued Products, 2022 (Contd..2)
List of Figures
Figure 1: Number of Products under Development for Schizophrenia, 2022
Figure 2: Number of Products under Development by Companies, 2022
Figure 3: Number of Products under Development by Universities/Institutes, 2022
Figure 4: Number of Products by Top 10 Targets, 2022
Figure 5: Number of Products by Stage and Top 10 Targets, 2022
Figure 6: Number of Products by Top 10 Mechanism of Actions, 2022
Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Figure 8: Number of Products by Routes of Administration, 2022
Figure 9: Number of Products by Stage and Routes of Administration, 2022
Figure 10: Number of Products by Molecule Types, 2022
Figure 11: Number of Products by Stage and Molecule Types, 2022

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings